Lakewood Amedex
Biopharmaceutical company focused on discovery and development of locally administered antimicrobial agents. The organization discovered a novel class of small nucleotide-derivative antimicrobials and is developing a lead topical gel candidate for infected diabetic foot ulcers (iDFU). Activities include preclinical in vitro/in vivo characterization, formulation development for topical and inhaled delivery, early clinical studies, and intellectual property management.
Industries
Nr. of Employees
small (1-50)
Lakewood Amedex
Patents
Products
Lead topical antimicrobial candidate (gel)
A lead locally applied antimicrobial formulated as a topical gel for treatment of skin and wound infections; developed for infected diabetic foot ulcers and advanced to Phase 2 clinical development.
Nu-3
Lead compound for Infected Diabetic Foot Ulcers (iDFU), topically applied and utilizing the Bisphosphocin class to rapidly kill bacteria and fungi by depolarizing microbial cell membranes.
Lead topical antimicrobial candidate (gel)
A lead locally applied antimicrobial formulated as a topical gel for treatment of skin and wound infections; developed for infected diabetic foot ulcers and advanced to Phase 2 clinical development.
Nu-3
Lead compound for Infected Diabetic Foot Ulcers (iDFU), topically applied and utilizing the Bisphosphocin class to rapidly kill bacteria and fungi by depolarizing microbial cell membranes.
Services
Discovery and preclinical characterization of novel antimicrobial compounds, including in vitro spectrum and biofilm testing and in vivo toxicology studies.
Discovery and preclinical characterization of novel antimicrobial compounds, including in vitro spectrum and biofilm testing and in vivo toxicology studies.
Expertise Areas
- Antimicrobial discovery
- Preclinical microbiology and biofilm testing
- Formulation development for local delivery
- Preclinical toxicology
Key Technologies
- Membrane-disruption antimicrobial mechanism
- Time-kill assays
- Biofilm efficacy assays
- Topical gel formulation
News & Updates
Peer-reviewed article describing in vitro and in vivo characterization of the lead nucleotide-derivative antimicrobial candidate and its potency against resistant pathogens.
Conference presentation on structure-activity relationships of the antimicrobial class at a scientific meeting.
Portfolio comprising 99 patent applications with 71 allowed and 28 pending, providing composition, formulation, use, and process protection with coverage through 2038 and extending to 2044 for recent filings once issued.
Peer-reviewed article describing in vitro and in vivo characterization of the lead nucleotide-derivative antimicrobial candidate and its potency against resistant pathogens.
Conference presentation on structure-activity relationships of the antimicrobial class at a scientific meeting.
Portfolio comprising 99 patent applications with 71 allowed and 28 pending, providing composition, formulation, use, and process protection with coverage through 2038 and extending to 2044 for recent filings once issued.